Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.60 |
| ▸ | DHODH | Q02127 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439291 | 0.88 | PARP1 (0.64) | PARP1DHODHGAANPC1RAB9A | |
| SCHEMBL7477311 | 0.82 | PKN1 (0.65) | PARP1DHODHGAANPC1RAB9A | |
| SCHEMBL22452564 | 0.81 | HDAC6 (0.60) | PARP1GAARPS6KA3MAPTPOLB | |
| SCHEMBL31027910 | 0.81 | HDAC6 (0.60) | PARP1GAARPS6KA3MAPTPOLB | |
| SCHEMBL5024091 | 0.81 | NPC1 (0.54) | PARP1DHODHGAANPC1RAB9A | |
| SCHEMBL31027957 | 0.80 | DHODH (0.59) | PARP1DHODHGAANPC1RAB9A | |
| SCHEMBL1894334 | 0.79 | PARP1 (0.67) | PARP1GAANPC1RAB9AALDH1A1 | |
| SCHEMBL24067330 | 0.79 | DHODH (0.58) | PARP1DHODHGAANPC1RAB9A | |
| SCHEMBL18300830 | 0.79 | DHODH (0.56) | PARP1DHODHGAANPC1RAB9A | |
| SCHEMBL56853 | 0.79 | PARP1 (0.62) | PARP1DHODHGAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0001246-A1 | Preparation of 2-(3'- or 4'-aminophenyl)-5(or 6)-aminobenzimidazoles | CASSELLA Aktiengesellschaft (DE) | 1979-04-04 | — | — | EP | claimed |
| CN-105789669-A | Phosphonic acid doped cross-linked sulfonated polyiminobenzimidazole high-temperature proton exchange membrane and preparation method thereof | 武汉理工大学 | 2016-07-20 | — | — | CN | disclosed |
| EP-1494668-A4 | USE OF BENZIMIDAZOLE ANALOGS IN THE TREATMENT OF CELL PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20050277686-A1 | Benzimidazole compounds for regulating IgE | SIRCAR JAGADISH C | 2005-12-15 | — | — | US | disclosed |
| US-20050197375-A1 | Use of benzimidazole analogs in the treatment of cell proliferation | AVANIR PHARMACEUTICALS | 2005-09-08 | — | — | US | disclosed |
| US-6911462-B2 | Benzimidazole compounds for regulating IgE | AVANIR PHARMACEUTICALS (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1494668-A2 | USE OF BENZIMIDAZOLE ANALOGS IN THE TREATMENT OF CELL PROLIFERATION | Avanir Pharmaceuticals (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040116388-A1 | triazine compoound inhibitors of enzymes that catalyze phosphoryl transfer and/or that bind ATP/GTP nucleotides | AMGEN INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2003082186-A2 | USE OF BENZIMIDAZOLE ANALOGS IN THE TREATMENT OF CELL PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | AVANIR PHARMACEUTICALS | 2003-05-29 | — | — | US | disclosed |
| EP-0001246-B1 | PREPARATION OF 2-(3'- OR 4'-AMINOPHENYL)-5(OR 6)-AMINOBENZIMIDAZOLES | CASSELLA Aktiengesellschaft (DE) | 1981-02-25 | — | — | EP | disclosed |
| US-4192947-A | REACTING DIAMINO NITROBENZENE WITH NITROBENZOYL CHLORIDE, CYCLIZING ANILIDE IN AQUEOUS ALKALI, REDUCING NITRO GROUPS WITH SULFIDE | CASSELLA AKTIENGESELLSCHAFT (DE) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100582-A1 | Benzimidazole compounds for regulating IgE | FCER2, SERPINB1, BRPF3 | PARP1 2352/4885DHODH 1391/4885GAA 1554/4885 |
| US-20050277686-A1 | Benzimidazole compounds for regulating IgE | FCER2, SERPINB1, BRPF3 | PARP1 2352/4885DHODH 1391/4885GAA 1554/4885 |
| US-20050197375-A1 | Use of benzimidazole analogs in the treatment of cell proliferation | MKI67, CCNI, CDKN1A | PARP1 318/4885DHODH 436/4885GAA 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.